食管癌、胃癌、结肠癌、直肠癌、肝癌、胰腺癌、肺癌与卵巢癌患者放疗使用情况:国际癌症基准合作组织(ICBP)基于人群的研究
该基于人群研究纳入挪威、英国四地区、加拿大九省和澳大利亚两州2012至2017年诊断的八类癌症患者共786,955例,分析诊断前31天至诊断后365天放疗使用及启动时间的辖区间差异。结果显示放疗使用率辖区间差异大(如食管癌合并估计50.2%,95%预测区间17.8–82.4),85–99岁患者放疗使用几率低于65–74岁(OR 0.38,95%预测区间0.20–0.73),中位启动时间亦存在辖区间差异。
要点
- 食管癌放疗使用合并估计50.2%(95%预测区间17.8–82.4),辖区间差异大。
- 85–99岁患者放疗使用几率低于65–74岁(OR 0.38,95%预测区间0.20–0.73)。
- 食管癌中位首程放疗时间合并估计62.0天(95%预测区间11.3–112.8天)。
核心结论
- 放疗使用和启动时间存在大的辖区间差异,并伴有大且可变的年龄差异;需明确这些差异的 underlying 原因以指导改善患者结局。
研究设计与样本
- 基于人群研究,使用挪威、英国四地区(英格兰、北爱尔兰、苏格兰、威尔士)、加拿大九省和澳大利亚两州的数据。
- 纳入2012年1月1日至2017年12月31日诊断的15–99岁八类癌症患者,排除索引癌症诊断前5年至后1年内或研究期间发生其他原发癌者。
- 共902,312例新诊断患者中115,357例(12.8%)不符合纳入标准,786,955例纳入分析。
- 评估诊断前31天至诊断后365天放疗使用及启动时间,采用随机效应Meta分析量化辖区间差异(95%预测区间)。
主要发现
- 放疗使用辖区间差异大:食管癌95%预测区间17.8–82.4(合并估计50.2%),直肠癌35.5–55.2(45.2%),肺癌28.6–54.0(40.6%),胃癌4.6–53.6(19.0%)。
- 2–3期直肠癌辖区间差异大于所有直肠癌患者(95%预测区间37.0–84.6;合并估计64.2%)。
- 胰腺癌(95%预测区间1.7–16.5%)、肝癌(1.8–11.2%)、结肠癌(1.6–5.0%)和卵巢癌(0.8–7.6%)放疗使用不频繁但存在差异。
- 85–99岁患者放疗使用几率低于65–74岁(OR 0.38;95%预测区间0.20–0.73),该年龄差异存在大的辖区间变异。
- 女性放疗使用几率略低于男性(OR 0.88,95%预测区间0.77–1.01);中位首程放疗时间辖区间差异大(食管癌合并估计62.0天,95%预测区间11.3–112.8天;直肠癌合并估计56.0天,95%预测区间34.7–77.3天);85–99岁患者较65–74岁中位时间短9.5天(95%预测区间-26.4至7.4)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is little evidence on variation in radiotherapy use in different countries, although it is a key treatment modality for some patients with cancer. Here we aimed to examine such variation. METHODS: This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), nine Canadian provinces (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan), and two Australian states (New South Wales and Victoria). Patients aged 15-99 years diagnosed with cancer in eight different sites (oesophageal, stomach, colon, rectal, liver, pancreatic, lung, or ovarian cancer), with no other primary cancer diagnosis occurring within the 5 years before to 1 year after the index cancer diagnosis or during the study period were included in the study. We examined variation in radiotherapy use from 31 days before to 365 days after diagnosis and time to its initiation, alongside related variation in patient group differences. Information was obtained from cancer registry records linked to clinical or patient management system data, or hospital administration data. Random-effects meta-analyses quantified interjurisdictional variation using 95% prediction intervals (95% PIs). FINDINGS: Between Jan 1, 2012, and Dec 31, 2017, of 902 312 patients with a new diagnosis of one of the studied cancers, 115 357 (12·8%) did not meet inclusion criteria, and 786,955 were included in the analysis. There was large interjurisdictional variation in radiotherapy use, with wide 95% PIs: 17·8 to 82·4 (pooled estimate 50·2%) for oesophageal cancer, 35·5 to 55·2 (45·2%) for rectal cancer, 28·6 to 54·0 (40·6%) for lung cancer, and 4·6 to 53·6 (19·0%) for stomach cancer. For patients with stage 2-3 rectal cancer, interjurisdictional variation was greater than that for all patients with rectal cancer (95% PI 37·0 to 84·6; pooled estimate 64·2%). Radiotherapy use was infrequent but variable in patients with pancreatic (95% PI 1·7 to 16·5%), liver (1·8 to 11·2%), colon (1·6 to 5·0%), and ovarian (0·8 to 7·6%) cancer. Patients aged 85-99 years had three-times lower odds of radiotherapy use than those aged 65-74 years, with substantial interjurisdictional variation in this age difference (odds ratio [OR] 0·38; 95% PI 0·20-0·73). Women had slightly lower odds of radiotherapy use than men (OR 0·88, 95% PI 0·77-1·01). There was large variation in median time to first radiotherapy (from diagnosis date) by cancer site, with substantial interjurisdictional variation (eg, oesophageal 95% PI 11·3 days to 112·8 days; pooled estimate 62·0 days; rectal 95% PI 34·7 days to 77·3 days; pooled estimate 56·0 days). Older patients had shorter median time to radiotherapy with appreciable interjurisdictional variation (-9·5 days in patients aged 85-99 years vs 65-74 years, 95% PI -26·4 to 7·4). INTERPRETATION: Large interjurisdictional variation in both use and time to radiotherapy initiation were observed, alongside large and variable age differences. To guide efforts to improve patient outcomes, underlying reasons for these differences need to be established. FUNDING: International Cancer Benchmarking Partnership (funded by the Canadian Partnership Against Cancer, Cancer Council Victoria, Cancer Institute New South Wales, Cancer Research UK, Danish Cancer Society, National Cancer Registry Ireland, The Cancer Society of New Zealand, National Health Service England, Norwegian Cancer Society, Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry, DG Health and Social Care Scottish Government, Western Australia Department of Health, and Public Health Wales NHS Trust).
引用
- McPhail S, Barclay ME, Swann R, et al. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study. Lancet Oncol. 2024. PMID: 38423049. doi:10.1016/S1470-2045(24)00032-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。